Gossamer Bio, Inc. (GOSS) SEC Filings & Earnings Calls

Activist investor reducing stake below 5% threshold

“On September 24, 2026, Valence ceased to be the beneficial owner of more than 5 percent of the class of securities.” · word for word

Short positions held by activist investor

“As a result of the Reverse Stock Split, Valence and Cogence maintain open short positions referencing 44,364 and 2,290 Common Shares, respectively.” · word for word

FDA may not accept or approve NDA; company entirely dependent on seralutinib success.

“the FDA may determine that the Company’s NDA does not qualify for filing and may not accept or approve the filing; the Company’s future performance is dependent entirely on the success of seralutinib”

Dilution Risk

“The release of 20,086,929 freely traded shares onto the market, or the perception that such shares will or could come onto the market, could have an adverse effect on the trading price of our stock.” · word for word

Regulatory Approval Dependency

“If the Second Closing does not occur on or before December 31, 2026, the obligations of the Company and the Purchasers relating to the Second Closing Pre-Funded Warrants and FDA Approval Warrants will automatically terminate.” · word for word

Reverse stock split may not sustain bid price above $1; delisting risk remains.

“May not result in sustained increase in stock price; may not satisfy Nasdaq minimum bid price requirement.”

Dilution risk from warrant exercise and preferred stock conversion; stockholder approval required for common stock issuance.

“pre-funded warrants and FDA Approval Warrants will be exercisable for shares of the Company’s non-voting convertible preferred stock... Following stockholder approval, each series of non-voting convertible preferred stock will be automatically converted into common stock” · word for word

Milestone dependency: second closing contingent on NDA acceptance in 2026; failure could reduce available capital.

“The investors’ obligations to fund the second closing remain subject to the NDA Acceptance Milestone occurring in 2026” · word for word

FDA approval risk

“The FDA's ultimate determination on approvability will be made upon review of the complete NDA, and there can be no assurance that the FDA will accept the NDA for filing or ultimately approve seralutinib.” · word for word

Delisting risk

“On April 8, 2026, we received written notice from the Nasdaq Stock Market staff notifying us that, for the last 30 consecutive business days, the bid price for our common stock had closed below the minimum $1.00 per share requirement” · word for word

Dilution risk

“In connection with the Exchange Offer completed in June 2026, we issued 254,150,441 shares of common stock, 33,402,727 Prefunded Warrants and 135,789,000 Purchase Warrants, which resulted in substantial dilution to our existing stockholders.” · word for word

Liquidity/covenant risk

“The 2030 Notes Indenture also requires us to maintain minimum liquidity of $40 million, subject to reduction upon achievement of certain milestones, and contains a springing maturity date of March 2, 2027 if more than $4.0 million of the 2027 Notes remain outstanding at such time.” · word for word

Going concern risk

“We have incurred substantial operating losses since our inception and expect to continue to incur significant operating losses for the foreseeable future and may never become profitable.” · word for word

Clinical and regulatory risk; NDA submission subject to FDA review.

“NDA submission for seralutinib planned for September 2026; FDA approval decision expected Q3 2027.”

Cash runway limited; sufficient only into Q1 2027.

“Cash, cash equivalents and marketable securities totaled $57.0 million; expected to fund operations into Q1 2027.” · word for word

Regulatory risk: FDA may not accept NDA or approve seralutinib; review issues noted.

“FDA characterized the degree of statistical significance and the magnitude of the treatment effect observed in PROSERA as review issues rather than filing issues.” · word for word

Financial risk: Company may need additional funding to support development and commercialization.

“Preliminary cash of $57M may not be sufficient for all planned activities.”

Massive dilution from authorized share increase and reverse stock split

“Authorized shares increased from 700M to 4B; reverse stock split approved”

Shareholder dilution risk from convertible securities.

“Conversion rate and warrant exercise price disclosed.”

Substantial shareholder dilution from exchange offer.

“Issuance of new convertible notes, common stock, and warrants.”

Significant dilution risk from new shares and warrants

“The Issuer issued 254,150,441 New Shares, 33,402,727 Prefunded Warrants and 135,789,000 Purchase Warrants, which could significantly dilute existing shareholders if exercised or converted.”

High leverage and interest burden from new secured notes

“The New Convertible Notes bear interest at a rate of 7.50% per annum and are secured, first lien obligations, increasing the company's fixed charges and secured debt.” · word for word

Delisting risk from Nasdaq non-compliance

“The Nasdaq Listing Qualifications Department notified us on April 8, 2026 that the bid price of our Common Stock had closed at less than $1.00 per share over the previous 30 consecutive business days” · word for word

Substantial dilution from exchange offer and potential conversion

“immediately following the Closing Date, the Existing Noteholders would own in the aggregate 317,647,058 shares, or approximately 57.5%, of the issued and outstanding Common Stock” · word for word

Cash settlement risk if proposals not approved

“If we are required to pay cash upon conversion of the New Convertible Notes, or upon exercise of the Purchase Warrants, it would reduce our available cash flow and limit our cash flow available for operations” · word for word

High debt service cost

“Interest on the New Convertible Notes will be paid semi-annually at a rate of 7.50% per annum” · word for word

High dilution risk from convertible notes and warrants with anti-dilution adjustments.

“Detailed terms of New Convertible Notes Indenture and Purchase Warrant Agreement.”

Dilution risk from exchange offer supported by majority noteholders.

“Transaction Support Agreement details.”

Going concern risk

“The Company’s existing cash and cash equivalents are not sufficient to fund operating plans for at least one year from the issuance date of these financial statements. Accordingly, these conditions raise substantial doubt about the Company’s ability to continue as a going concern.” · word for word

Clinical trial failure risk

“Seralutinib demonstrated a placebo-adjusted improvement in the primary endpoint, 6MWD at Week 24, of 13.3 meters (p = 0.0320), missing the prespecified alpha threshold of 0.025.” · word for word

Customer concentration risk

“During the three months ended March 31, 2026, Chiesi was the Company's principal customer, accounting for 100% of its revenue.” · word for word

Clinical trial delay risk

“Site initiated. No patient enrollment.” · word for word

Capital allocation risk after PROSERA results

“In light of the topline results from the Phase 3 PROSERA study and need to evaluate capital allocation, the compensation committee determined our corporate performance percentage to be 65% of the target performance level for 2025.” · word for word

Primary endpoint miss for lead drug candidate seralutinib in Phase 3 PAH trial; regulatory path uncertain.

“PROSERA narrowly missed prespecified statistical threshold for its primary endpoint.”

Workforce reduction and pipeline pause indicate financial strain and strategic uncertainty.

“Company implemented a reduction in force and paused SERANATA enrollment.”

Cash burn rate high; limited runway into Q1 2027 without new financing or partnership.

“Cash $136.9M; expects to fund operations into Q1 2027.”

Clinical trial failure risk

“Seralutinib demonstrated a placebo-adjusted improvement in the primary endpoint, six-minute walk distance (6MWD) at Week 24, of 13.3 meters (p = 0.0320), missing the prespecified alpha threshold of 0.025.” · word for word

Regulatory approval uncertainty

“We plan to engage with the FDA, including through requesting a Type C meeting, to understand their perspective on the totality of the PROSERA and TORREY datasets and potential regulatory paths forward.”

Liver enzyme elevation safety signal

“Transaminase elevations of three times or greater of the upper limit of normal were observed in 13% of patients receiving seralutinib and 1% of patients receiving placebo.” · word for word

Significant operating losses and accumulated deficit

“We have incurred significant operating losses since our inception and expect to continue to incur significant operating losses for the foreseeable future and may never become profitable.” · word for word

Dependence on seralutinib success

“We are a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of PH, including PAH and PH-ILD.” · word for word

Need for additional capital

“We will need to raise substantial additional capital in the future.” · word for word

Clinical trial risks

“Clinical and preclinical development timelines, the probability of success and development costs can differ materially from expectations.” · word for word

Single product dependency on seralutinib; Phase 3 readout binary risk

“All pipeline is seralutinib; PROSERA topline in Feb 2026 is pivotal.”

Net loss increasing; R&D spend rising

“Net loss $48.2M vs prior period; R&D up 30% YoY.”